NYSE:PHR

Stock Analysis Report

Executive Summary

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada.

Snowflake

Fundamentals

Concerning outlook with worrying balance sheet.

Share Price & News

How has Phreesia's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-5.5%

NYSE:PHR

-1.0%

US Healthcare Services

-1.0%

US Market


1 Year Return

n/a

NYSE:PHR

16.8%

US Healthcare Services

-0.4%

US Market

No trading data on PHR.

No trading data on PHR.


Share holder returns

PHRIndustryMarket
7 Day-5.5%-1.0%-1.0%
30 Day11.1%-2.7%-3.3%
90 Dayn/a5.3%0.8%
1 Yearn/a16.9%16.8%1.9%-0.4%
3 Yearn/a53.6%53.3%39.4%30.4%
5 Yearn/a57.9%56.9%54.2%37.1%

Price Volatility Vs. Market

How volatile is Phreesia's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Phreesia undervalued based on future cash flows and its price relative to the stock market?


Intrinsic Value Based on Future Cash Flows

Phreesia's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Phreesia's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Phreesia is loss making, we can't compare its value to the US Healthcare Services industry average.

Phreesia is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Phreesia, we can't assess if its growth is good value.


Price Based on Value of Assets

Phreesia has negative assets, we can't compare the value of its assets to the US Healthcare Services industry average.


Next Steps

Future Growth

How is Phreesia expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

55.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Phreesia's revenue is expected to grow by 17.6% yearly, however this is not considered high growth (20% yearly).

Phreesia is not considered high growth as it is expected to be loss making for the next 1-3 years.

Phreesia's revenue growth is expected to exceed the United States of America market average.

Unable to compare Phreesia's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Phreesia's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Phreesia will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has Phreesia performed over the past 5 years?

-35.6%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Phreesia does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Phreesia's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Phreesia's 1-year growth to the US Healthcare Services industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Phreesia has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Phreesia has efficiently used its assets last year compared to the US Healthcare Services industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Phreesia improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Phreesia's financial position?


Financial Position Analysis

Phreesia is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Phreesia's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Phreesia has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Phreesia's debt level has increased considering it has negative shareholder equity.


Balance Sheet

High level of physical assets or inventory.

Phreesia has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Phreesia has less than a year of cash runway based on current free cash flow.

Phreesia has less than a year of cash runway if free cash flow continues to reduce at historical rates of -72.4% each year.


Next Steps

Dividend

What is Phreesia's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Phreesia's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Phreesia's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Phreesia has not reported any payouts.

Unable to verify if Phreesia's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Phreesia has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Phreesia's salary, the management and board of directors tenure and is there insider trading?

4.6yrs

Average management tenure


CEO

Chaim Indig (41yo)

4.6yrs

Tenure

US$510,249

Compensation

Mr. Chaim Indig Co-Founded Phreesia, Inc. in 2005 and serves as its Chief Executive Officer and Director since January 2005. Mr. Indig has helped to revolutionize the patient check-in experience. Under his ...


CEO Compensation Analysis

Chaim's remuneration is lower than average for companies of similar size in United States of America.

Insufficient data for Chaim to compare compensation growth.


Management Age and Tenure

4.6yrs

Average Tenure

44.5yo

Average Age

The tenure for the Phreesia management team is about average.


Board Age and Tenure

4.6yrs

Average Tenure

57yo

Average Age

The tenure for the Phreesia board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Amy VanDuyn (46yo)

    Senior Vice President of Human Resources

    • Tenure: 9.3yrs
  • Tom Altier (69yo)

    Chief Financial Officer

    • Tenure: 6.7yrs
    • Compensation: $380.12k
  • Michael Davidoff (46yo)

    Senior Vice President of Marketing & Business Development

    • Tenure: 0.6yrs
  • Chaim Indig (41yo)

    Co-Founder

    • Tenure: 4.6yrs
    • Compensation: $510.25k
  • Evan Roberts (40yo)

    Co-Founder & COO

    • Tenure: 14.6yrs
    • Compensation: $380.12k
  • Daniel Nathan (43yo)

    Chief Technology Officer

    • Tenure: 0.5yrs
  • Will Rideout

    Vice President of Sales

    • Tenure: 8.4yrs
  • David Linetsky (39yo)

    Senior Vice President of Life Sciences

    • Tenure: 0.4yrs
  • Ralph Gonzales

    Chief Medical Advisor

  • Charles H. Kallenbach (56yo)

    General Counsel & Secretary

    • Tenure: 2.8yrs
    • Compensation: $421.01k

Board Members

  • Chaim Indig (41yo)

    Co-Founder

    • Tenure: 4.6yrs
    • Compensation: $510.25k
  • Mark Smith (68yo)

    Director

    • Tenure: 0.8yrs
    • Compensation: $186.40k
  • Michael Weintraub (57yo)

    Chairman

    • Tenure: 14.6yrs
    • Compensation: $342.50k
  • Gillian Munson (48yo)

    Director

    • Tenure: 0.3yrs
  • Ed Cahill (66yo)

    Director

    • Tenure: 11.8yrs
  • Mark Blais

    Member of Medical Advisory Board

  • Michael Brodman

    Member of Medical Advisory Board

  • Richard Jackson

    Member of Medical Advisory Board

  • Elsa-Grace Giardina

    Member of Medical Advisory Board

  • Lee Schwamm

    Member of Medical Advisory Board

Company Information

Phreesia, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Phreesia, Inc.
  • Ticker: PHR
  • Exchange: NYSE
  • Founded: 2005
  • Industry: health care technology
  • Sector: healthcare
  • Market Cap: US$946.967m
  • Shares outstanding: 35.51m
  • Website: Click here

Number of Employees


Location

  • Phreesia, Inc.
  • 432 Park Avenue South
  • 12th Floor
  • New York
  • New York
  • 10016
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PHRNYSE (New York Stock Exchange)YesCommon StockUSUSDJul 2019
19PBST (Boerse-Stuttgart)YesCommon StockDEEURJul 2019
19PDB (Deutsche Boerse AG)YesCommon StockDEEURJul 2019

Biography

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company’s Phreesia Platform offers a suite of solutions to ma ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/18 00:57
End of Day Share Price2019/08/16 00:00
Earnings2019/04/30
Annual Earnings2019/01/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.